Company
Company
Arrows show the direction of the relationship. Filter to focus on a business area.
Mediar is also progressing novel fibro-inflammatory targets as part of a recently announced collaboration with Ono Pharmaceutical.View source
Mediar is conducting the Phase 2 WISPer study under a global licensing agreement with Eli Lilly and Company.View source
Showing 1 to 2 of 2
Read the assertion alongside its sources. Expand a row to inspect the evidence.
Mediar is also progressing novel fibro-inflammatory targets as part of a recently announced collaboration with Ono Pharmaceutical.
PR Newswire news releases · 2026-10-07 19:08
Mediar is also progressing novel fibro-inflammatory targets as part of a recently announced collaboration with Ono Pharmaceutical.View source
Mediar is conducting the Phase 2 WISPer study under a global licensing agreement with Eli Lilly and Company.
PR Newswire news releases · 2026-10-07 19:08
Mediar is conducting the Phase 2 WISPer study under a global licensing agreement with Eli Lilly and Company.View source
Showing 1 to 2 of 2
Valuation data is available on Pro and Research.
Included in ProNot available: Company signals · Financials · Filings · Guidance
